The DUSP3 Knockout A2780 Polyclonal Cells are a CRISPR/Cas9-edited heterogeneous cell population derived from the A2780 cell line, with targeted disruption of the dual-specificity phosphatase 3 (DUSP3) gene. This polyclonal format preserves a mixed knockout background, providing a robust loss-of-function model without clonal selection biases. The gene disruption eliminates DUSP3 protein expression, enabling functional studies of DUSP3-mediated signaling regulation.
The parental A2780 line is an adherent human epithelial ovarian carcinoma cell model, derived from an untreated adenocarcinoma. It is widely employed to investigate ovarian tumorigenesis, metastatic behavior, and drug resistance, making it a relevant platform for exploring oncogenic signaling networks and therapeutic vulnerabilities in ovarian cancer.
DUSP3 encodes a dual-specificity phosphatase that dephosphorylates and inactivates key MAP kinases??ERK1/2 (MAPK3/MAPK1), JNK (MAPK8/MAPK9), and p38 (MAPK14)??as well as the transcription factors STAT5A and STAT5B. This protein is regulated by upstream signals including EGFR, reactive oxygen species, growth factors, and insulin, and it physically interacts with ERK2, JNK1, p38??, STAT5A, and EGFR. Upon EGFR stimulation, the adaptor protein GRB2 recruits SOS to activate RAS, initiating a kinase cascade through RAF, MEK, and ERK. DUSP3 serves as a phosphatase node that directly dephosphorylates these MAPKs to attenuate signaling, thereby controlling cell proliferation and apoptosis. Its loss leads to constitutive MAPK activation, driving oncogenic signaling.
In A2780 cells, DUSP3 knockout results in sustained phosphorylation of ERK1/2, JNK, and p38, recapitulating the MAPK hyperactivation seen in aggressive ovarian carcinomas. This model is instrumental for studying the molecular mechanisms underlying chemoresistance, particularly to cisplatin and paclitaxel, and for evaluating the tumor-suppressive functions of DUSP3. It also informs research on breast and prostate cancers where DUSP3 dysregulation contributes to disease progression, and provides a genetically defined system to assess the impact of MAPK hyperactivation on ovarian cancer cell behavior.
Applications include dissecting DUSP3 function in MAPK pathways, exploring drug resistance mechanisms, and screening MAPK-targeting inhibitors. Typical assays include western blotting for phospho-ERK/JNK/p38, RT-qPCR for downstream targets, proliferation and migration assays, colony formation, apoptosis analysis, and drug sensitivity testing. For further information, contact Ascent Research.
